In this new role, Dr Brainin will be responsible for advancing the clinical development of ISM-001, a treatment for chronic stable angina (CSA).
With a combination of clinical, medical and venture investing experience, Dr Brainin has invested in multiple early-stage therapeutics companies, supported corporate and business development strategies and advised Boards of Directors, including for AnaCardio and Nephro DI.
Dr Brainin said: “What excites me about IsomAb is that ISM-001 is not just another VEGF therapy.
“The pioneering mechanistic and pharmacological data generated by the team shows that IsomAb’s unique approach targeting VEGF-A165b removes the brakes on angiogenesis that are applied in ischemic disease, allowing blood vessels to grow, remodel and create durable new arteries.
“Once proof of concept is demonstrated in the clinic, I envisage a clear pathway for regulatory, manufacturing and commercial success.”
IsomAb has also appointed Dr Anker Lundemose as Chair of the Board of Directors. Dr Lundemose has gained leadership experience at multiple companies, including OSI Pharmaceuticals, Prosidion and Mission Therapeutics.
Dr Lundemose said: “With strong preclinical results, a clear translational plan through clinical proof of concept, and Philip’s appointment as CEO, I believe IsomAb offers a major Series A investment opportunity and look forward to working with him to accelerate ISM‑001’s development into a much-needed breakthrough therapy for cardiovascular disease.”
